Jump to Main Contents
ncc en

Home > Information > What's New 2017

What's New 2017

Dec. 22, 2017
T. Matsuda takes office of International Association of Cancer Registries President
Dec. 18, 2017
Cancer Statistics in Japan; Table download
Dec. 14, 2017
National Cancer Center - IARC Seminar 2
Dec. 5, 2017
NCC signs comprehensive MoU with WHO/IARC
Nov. 27, 2017
Asian Early Phase Oncology Drug Development Consortium Formed
Nov. 21, 2017
New Agreement with National Cancer Center, Indonesia
Nov. 14, 2017
Lithuanian Health Minister Visit
Oct. 30, 2017
Cancer Statistics in Japan; Table download
Oct. 27, 2017
Collaborative Research on Fully-personalized Cancer Neoantigen Vaccine
Oct. 27, 2017
Projected Cancer Statistics, 2017
Oct. 26, 2017
National Cancer Center - IARC Seminar 1
Oct. 16, 2017
Commencement of Collaborative Research on Measurement of Exosomes in Blood from Cancer Patients
Aug. 3, 2017
Japan-Singapore lead international research in discovering potential targeted treatments for biliary tract cancer
Aug. 1, 2017
On-Table Adaptive Radiation Therapy
Jul. 31, 2017
Genomic medicine in Rare Cancers:
A collaboration between the industry and academia
Jul. 21, 2017
Cancer Registration Seminar in Myanmar
Jul. 11, 2017
Cancer Statistics in Japan; Table download(Link to Cancer Information Service)
Jun. 26, 2017
A novel biomarker for development of a new screening technique for early-stage pancreatic cancer and precancerous conditions associated with risk of pancreatic malignancy - experimental screening in Kagoshima Prefecture
Jun. 16, 2017
National Cancer Center hosts Iranian Delegation
May 30, 2017
WHO/International Agency for Research on Cancer establishes National Cancer Center as Global Initiative for Cancer Registry Development Collaborating Centre
Apr. 27, 2017
Elucidation of the mechanism of MLL-rearranged leukemia Use of two molecularly targeted drugs as novel therapy
Mar. 1, 2017
Commencement of Phase 1 Trial for the Mutant IDH1 Inhibitor (DS-1001)Targeting Malignant Brain Tumors
Feb. 28, 2017
Malignant extracellular vesicles derived from ovarian cancer cells facilitate peritoneal dissemination, and the vesicles can be promising targets for improving patient outcomes.
Feb. 21, 2017
Signing MOU with the National Cancer Research Institute (UK)